Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAIDs vs. Tylenol

This article was originally published in The Tan Sheet

Executive Summary

Non-steroidal anti-inflammatory drugs are superior to acetaminophen for improving knee and hip pain in people with osteoarthritis, a review published in The Cochrane Database of Systematic Reviews finds. Tanveer Towheed, MD, Queen's University, Ontario, et al., analyzed 15 randomized controlled trials gleaned from a search of databases including MEDLINE and EMBASE; the studies dated from 1994 to July 2005 and lasted an average of six weeks. Researchers reviewed data on almost 6,000 people with osteoarthritis who took 4,000 mg of acetaminophen (McNeil's Tylenol) per day with those who took placebo or NSAID. Subjects who took NSAIDs reported lower levels of pain and increased movement; "in osteoarthritis subjects with moderate-to-severe levels of pain, NSAIDs appear to be more effective than acetaminophen," Towheed et al. state...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel